{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:59:39Z","timestamp":1767859179764,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.12.017","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T07:41:52Z","timestamp":1671694912000},"page":"903-913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models"],"prefix":"10.1016","volume":"41","author":[{"given":"Stephanie","family":"Curry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin M.","family":"Kaufhold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan A.","family":"Monslow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"McGuinness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise K.","family":"Nawrocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie L.","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph G.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.12.017_b0005","unstructured":"US Centers for Disease Control and Prevention. Pneumococcal Disease for Laboratorians. https:\/\/www.cdc.gov\/pneumococcal\/laboratorians.html [Accessed 31 May 2022]."},{"key":"10.1016\/j.vaccine.2022.12.017_b0010","series-title":"Streptococcus Pneumoniae Molecular Mechanisms of Host-Pathogen Interaction","first-page":"3","article-title":"Molecular Epidemiology of Streptococcus pneumoniae","author":"Ramirez","year":"2015"},{"key":"10.1016\/j.vaccine.2022.12.017_b0015","series-title":"Streptococcus Pneumoniae Molecular Mechanisms of Host-Pathogen Interaction","first-page":"21","article-title":"Antibiotic Resistance of Pneumococci","author":"McGee","year":"2015"},{"key":"10.1016\/j.vaccine.2022.12.017_b0020","unstructured":"US Centers for Disease Control and Prevention. Pneumococcal Disease Surveillance and Reporting. https:\/\/www.cdc.gov\/pneumococcal\/surveillance.html [accessed 31 May 2022]."},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.017_b0025","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0377","article-title":"Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease","volume":"145","author":"Berman-Rosa","year":"2020","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.017_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2016.1277300","article-title":"Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world","volume":"13","author":"Cui","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.017_b0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41564-019-0651-y","article-title":"Designing ecologically optimized pneumococcal vaccines using population genomics","volume":"5","author":"Colijn","year":"2020","journal-title":"Nat Microbiol"},{"issue":"46","key":"10.1016\/j.vaccine.2022.12.017_b0040","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >= 65 years: updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Matanock","year":"2019","journal-title":"Mmwr-Morbid Mortal W"},{"key":"10.1016\/j.vaccine.2022.12.017_b0045","series-title":"Streptococcus Pneumoniae Molecular Mechanisms of Host-Pathogen Interaction","first-page":"59","article-title":"Vaccine Potential of Pneumococcal Proteins","author":"Ogunniyi","year":"2015"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2022.12.017_b0050","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1097\/INF.0000000000000084","article-title":"Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization","volume":"33","author":"Loo","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.12.017_b0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3947\/ic.2016.48.4.257","article-title":"Indirect effects of pneumococcal conjugate vaccines in national immunization programs for children on adult pneumococcal disease","volume":"48","author":"Kim","year":"2016","journal-title":"Infect Chemother"},{"key":"10.1016\/j.vaccine.2022.12.017_b0060","doi-asserted-by":"crossref","first-page":"e0220453","DOI":"10.1371\/journal.pone.0220453","article-title":"Limited indirect effects of an infant pneumococcal vaccination program in an aging population","volume":"14","author":"van der Linden","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.017_b0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.carres.2004.12.009","article-title":"Full NMR assignment and revised structure for the capsular polysaccharide from Streptococcus pneumoniae type 15B","volume":"340","author":"Jones","year":"2005","journal-title":"Carbohydr Res"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.017_b0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0008-6215(87)80205-7","article-title":"Structural studies of the capsular polysaccharide from Streptococcus pneumoniae types 15B and 15C","volume":"162","author":"Jansson","year":"1987","journal-title":"Carbohydr Res"},{"issue":"11","key":"10.1016\/j.vaccine.2022.12.017_b0075","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.3390\/microorganisms9112245","article-title":"Serotypes in adult pneumococcal pneumonia in Spain in the era of conjugate vaccines","volume":"9","author":"Fernandez-Delgado","year":"2021","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.017_b0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/thoraxjnl-2019-213725","article-title":"Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013\u201318","volume":"75","author":"Pick","year":"2020","journal-title":"Thorax"},{"issue":"31","key":"10.1016\/j.vaccine.2022.12.017_b0085","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1016\/j.vaccine.2018.06.018","article-title":"Serotype distribution of invasive Streptococcus pneumoniae in adults 65years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010\u20132016","volume":"36","author":"Demczuk","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.017_b0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.017_b0095","doi-asserted-by":"crossref","unstructured":"Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2022;40(1):162-72 doi: 10.1016\/j.vaccine.2021.08.049.","DOI":"10.1016\/j.vaccine.2021.08.049"},{"issue":"7","key":"10.1016\/j.vaccine.2022.12.017_b0100","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"48","key":"10.1016\/j.vaccine.2022.12.017_b0105","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1016\/j.vaccine.2011.09.078","article-title":"Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model","volume":"29","author":"Skinner","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.017_b0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.vaccine.2016.12.055","article-title":"Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain","volume":"35","author":"Caro-Aguilar","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.017_b0115","unstructured":"He J, MacNair JE, Smith WJ, Winters MA, Joyce JG, Abeygunawardana C, et al. Enhancing Immunogenicity of Streptococcus Pneumoniae Polysaccharide-Protein Conjugates. Patent US-2021330777-A1. 28 Oct 2021."},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.017_b0120","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1016\/j.vaccine.2021.04.067","article-title":"Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice","volume":"39","author":"McGuinness","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.017_b0125","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/424596","article-title":"Tissue-specific contributions of pneumococcal virulence factors to pathogenesis","volume":"190","author":"Orihuela","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.017_b0130","doi-asserted-by":"crossref","first-page":"e1005337","DOI":"10.1371\/journal.ppat.1005337","article-title":"Pore-forming toxins induce macrophage necroptosis during acute bacterial pneumonia","volume":"11","author":"Gonzalez-Juarbe","year":"2015","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.017_b0135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/CVI.00415-08","article-title":"Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum","volume":"16","author":"Marchese","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.12.017_b0140","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4155\/bio-2020-0023","article-title":"Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"key":"10.1016\/j.vaccine.2022.12.017_b0145","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/CVI.05252-11","article-title":"Establishment of a new human pneumococcal standard reference serum, 007sp","volume":"18","author":"Goldblatt","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.12.017_b0150","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1128\/CVI.00437-15","article-title":"Assignment of weight-based antibody units for seven additional serotypes to a human pneumococcal standard reference serum, 007sp","volume":"22","author":"Goldblatt","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.12.017_b0155","first-page":"24","article-title":"Assignment of weight-based antibody units for four additional serotypes to a human antipneumococcal standard reference serum, 007sp","author":"Goldblatt","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"14","key":"10.1016\/j.vaccine.2022.12.017_b0160","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.4155\/bio-2020-0024","article-title":"Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.12.017_b0165","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/CVI.00112-06","article-title":"Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies","volume":"13","author":"Burton","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.017_b0170","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/CVI.00086-12","article-title":"Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20","volume":"19","author":"Burton","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.017_b0175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/cdli.4.4.415-422.1997","article-title":"Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells","volume":"4","author":"Romero-Steiner","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2022.12.017_b0180","doi-asserted-by":"crossref","unstructured":"Platt H, Omole T, Cardona J, Fraser NJ, Mularski RA, Andrews C, et al. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect Dis. 2022; Epub ahead of print Sep 15. https:\/\/doi.org\/10.1016\/S1473-3099(22)00526-6.","DOI":"10.1016\/S1473-3099(22)00526-6"},{"issue":"41","key":"10.1016\/j.vaccine.2022.12.017_b0185","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.12.017_b0190","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1086\/593339","article-title":"Differential effects of pneumococcal vaccines against serotypes 6A and 6C","volume":"198","author":"Park","year":"2008","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.017_b0195","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/JCM.02199-06","article-title":"Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae","volume":"45","author":"Park","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.12.017_b0200","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1128\/JCM.01984-08","article-title":"Temporal trends and molecular epidemiology of recently described serotype 6C of Streptococcus pneumoniae","volume":"47","author":"Nunes","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2022.12.017_b0205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0300985811429314","article-title":"Immunological variation between inbred laboratory mouse strains: points to consider in phenotyping genetically immunomodified mice","volume":"49","author":"Sellers","year":"2012","journal-title":"Vet Pathol"},{"key":"10.1016\/j.vaccine.2022.12.017_b0210","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","article-title":"Innate immune response in Th1- and Th2-dominant mouse strains","volume":"22","author":"Watanabe","year":"2004","journal-title":"Shock"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:21:22Z","timestamp":1759404082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22015316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22015316"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}